Proteomics Approach Screening Breast Cancer Drug Resistive And Sensitive Serum Marker

objective:(1) Comparative breast cancer before neoadjuvant chemotherapy, Serum protein expression patterns change of Chemotherapy sensitive patients, Hope of finding new forecasting chemotherapy useful serum protein markers. (2) Comparative breast cancer before neoadjuvant chemotherapy, Serum protein expression patterns change of Chemotherapy resistive patients, Hope of finding new forecasting chemotherapy resistive serum protein markers.methods:Using proteomics approach Screening breast cancer drug resistance sensitive and related serum protein markers.Ⅲperiod in patients with neoadjuvant chemotherapy for breast cancer research object, Use bi-directional gel electrophoresis technology and MALDI-TOF-TOF Comparative chemotherapy patients serum protein expression patterns before and after the changes.results:First we compare chemotherapy sensitive breast cancer patients serum protein expression patterns before and after the treatment of change, Screening and identified 11 differentially expressed proteins site. They then compared chemotherapy drug resistant breast cancer patients serum protein expression patterns before and after the treatment of change,13 differences were protein site. The analysis results show that had five proteins in two groups of patients in the same change trend. We will this kind of protein called "responsiveness" chemotherapy serum marker.6 protein levels in chemotherapy sensitive group raised or under-active specificity, The effectiveness of the prediction of breast cancer chemotherapy serum marker candidates.8 protein levels in chemotherapy drug resistance this specificity raised or fall, Is the forecast breast cancer chemotherapy drug resistance serum marker candidates.conclusions:According to the different molecular weight and protein andisoelectric point, Through two-way gel electrophoresis technology can bring people serum protein component separation, Using the analysis software, Find the differences between before and after chemotherapy serum protein. Breast cancer neoadjuvant chemotherapy neoadjuvant chemotherapy before and after the second cycle of serum protein expression level there exist differences. These differences for prediction of protein and resistant breast cancer chemotherapy sensitivity serum marker provides reference basis. For breast cancer and may provide a new thought new therapeutic targets.